ChitogenX, formerly OrthoRTI, shared its third quarter results for fiscal year 2023.
Five things to know:
1. During the third quarter, the company rebranded to reflect the expanded applications of its proprietary technology, according to a Dec. 29 news release.
2. The initial portion of U.S. clinical trials for the Ortho-R rotator cuff repair were completed.
3. ChitogenX partnered with California Medical Innovations Institute for collaborative projects in regenerative medicine.
4. The company decided to pursue sales of medical grade chitosan.
5. In December, the company secured $1.2 milloin to fund initiatives and operations related to rotator cuff tear repair.